Published in Gastroenterology on May 01, 2006
Virus-plus-susceptibility gene interaction determines Crohn's disease gene Atg16L1 phenotypes in intestine. Cell (2010) 6.79
The impact of the microbiota on the pathogenesis of IBD: lessons from mouse infection models. Nat Rev Microbiol (2010) 2.22
Toll-like receptors in inflammatory bowel diseases: a decade later. Inflamm Bowel Dis (2010) 1.79
Intestinal microbiota shifts towards elevated commensal Escherichia coli loads abrogate colonization resistance against Campylobacter jejuni in mice. PLoS One (2012) 1.63
Environmental risk factors for inflammatory bowel disease. Gastroenterol Hepatol (N Y) (2010) 1.48
Immunopathogenesis of IBD: current state of the art. Nat Rev Gastroenterol Hepatol (2015) 1.34
The role of infection in the aetiology of inflammatory bowel disease. J Gastroenterol (2010) 1.26
Role of the gut microbiota in inflammatory bowel disease pathogenesis: what have we learnt in the past 10 years? World J Gastroenterol (2014) 1.25
Campylobacter jejuni induces transcellular translocation of commensal bacteria via lipid rafts. Gut Pathog (2009) 1.24
Short- and long-term effects of bacterial gastrointestinal infections. Emerg Infect Dis (2008) 1.24
Hygiene hypothesis in inflammatory bowel disease: a critical review of the literature. World J Gastroenterol (2008) 1.21
Microbial induction of immunity, inflammation, and cancer. Front Physiol (2011) 1.20
Mucosal T-cell immunoregulation varies in early and late inflammatory bowel disease. Gut (2007) 1.18
Campylobacter polysaccharide capsules: virulence and vaccines. Front Cell Infect Microbiol (2012) 1.08
Environment and the inflammatory bowel diseases. Can J Gastroenterol (2013) 1.07
The intestinal microbiota dysbiosis and Clostridium difficile infection: is there a relationship with inflammatory bowel disease? Therap Adv Gastroenterol (2013) 1.00
Past trends and current status of self-reported incidence and impact of disease and nonbattle injury in military operations in Southwest Asia and the Middle East. Am J Public Health (2008) 0.98
Risk of inflammatory bowel disease following a diagnosis of irritable bowel syndrome. BMC Gastroenterol (2012) 0.97
Campylobacter jejuni disrupts protective Toll-like receptor 9 signaling in colonic epithelial cells and increases the severity of dextran sulfate sodium-induced colitis in mice. Infect Immun (2012) 0.93
The Crohn's disease: associated ATG16L1 variant and Salmonella invasion. BMJ Open (2013) 0.93
Environmental risk factors for inflammatory bowel diseases: a review. Dig Dis Sci (2014) 0.92
The role of bacteria in the pathogenesis of ulcerative colitis. J Signal Transduct (2012) 0.91
Dominant fecal microbiota in newly diagnosed untreated inflammatory bowel disease patients. Gastroenterol Res Pract (2013) 0.90
Seroprevalence of campylobacteriosis and relevant post-infectious sequelae. Eur J Clin Microbiol Infect Dis (2014) 0.89
Persistent infection of rhesus monkeys with 'Helicobacter macacae' and its isolation from an animal with intestinal adenocarcinoma. J Med Microbiol (2010) 0.89
Antagonistic activity of Lactobacillus acidophilus ATCC 4356 on the growth and adhesion/invasion characteristics of human Campylobacter jejuni. Curr Microbiol (2012) 0.88
Clinical onset of celiac disease after an episode of Campylobacter jejuni enteritis. Can J Gastroenterol (2007) 0.88
Pathogen-specific risk of chronic gastrointestinal disorders following bacterial causes of foodborne illness. BMC Gastroenterol (2013) 0.87
Helicobacter bilis colonization enhances susceptibility to Typhlocolitis following an inflammatory trigger. Dig Dis Sci (2011) 0.87
Viruses, autophagy genes, and Crohn's disease. Viruses (2011) 0.86
High frequency, spontaneous motA mutations in Campylobacter jejuni strain 81-176. PLoS One (2014) 0.83
The Microbiome Activates CD4 T-cell-mediated Immunity to Compensate for Increased Intestinal Permeability. Cell Mol Gastroenterol Hepatol (2017) 0.83
Multicenter case-control study of the risk factors for ulcerative colitis in China. World J Gastroenterol (2013) 0.83
Campylobacter jejuni induces transcytosis of commensal bacteria across the intestinal epithelium through M-like cells. Gut Pathog (2010) 0.83
Management of the returning traveler with diarrhea. Therap Adv Gastroenterol (2009) 0.81
Laboratory markers in ulcerative colitis: Current insights and future advances. World J Gastrointest Pathophysiol (2015) 0.81
Is There a Link Between H. Pylori and the Epidemiology of Crohn's Disease? Dig Dis Sci (2017) 0.81
The critical role of membrane cholesterol in salmonella-induced autophagy in intestinal epithelial cells. Int J Mol Sci (2014) 0.81
Inflammatory bowel disease in travelers: choosing the right vaccines and check-ups. World J Gastroenterol (2011) 0.80
Enteric disease surveillance under the AFHSC-GEIS: current efforts, landscape analysis and vision forward. BMC Public Health (2011) 0.80
Deregulation of intestinal anti-microbial defense by the dietary additive, maltodextrin. Gut Microbes (2015) 0.79
The differential effects of 1,25-dihydroxyvitamin D3 on Salmonella-induced interleukin-8 and human beta-defensin-2 in intestinal epithelial cells. Clin Exp Immunol (2016) 0.79
IBS and IBD - separate entities or on a spectrum? Nat Rev Gastroenterol Hepatol (2016) 0.79
Microbiome-Epigenome Interactions and the Environmental Origins of Inflammatory Bowel Diseases. J Pediatr Gastroenterol Nutr (2016) 0.78
The Novel Crohn's Disease Marker Anti-GP2 Antibody Is Associated with Ileocolonic Location of Disease. Gastroenterol Res Pract (2013) 0.78
Peripheral CD4+ T cell cytokine responses following human challenge and re-challenge with Campylobacter jejuni. PLoS One (2014) 0.78
Campylobacter jejuni Increases Flagellar Expression and Adhesion of Noninvasive Escherichia coli: Effects on Enterocytic Toll-Like Receptor 4 and CXCL-8 Expression. Infect Immun (2015) 0.78
Glial contributions to visceral pain: implications for disease etiology and the female predominance of persistent pain. Transl Psychiatry (2016) 0.78
Appendectomy does not decrease the risk of future colectomy in UC: results from a large cohort and meta-analysis. Gut (2016) 0.78
Risk factors and clinical implication of superimposed Campylobacter jejuni infection in patients with underlying ulcerative colitis. Gastroenterol Rep (Oxf) (2015) 0.77
Identification of Environmental Factors Associated with Inflammatory Bowel Disease in a Southwestern Highland Region of China: A Nested Case-Control Study. PLoS One (2016) 0.77
Diet and microbiota in inflammatory bowel disease: The gut in disharmony. World J Gastroenterol (2017) 0.75
Development and Application of a Plant-Based Diet Scoring System for Japanese Patients with Inflammatory Bowel Disease. Perm J (2016) 0.75
Diagnostic Yield of Routine Enteropathogenic Stool Tests in Pediatric Ulcerative Colitis. Ann Clin Lab Sci (2015) 0.75
Acute Infectious Gastroenteritis Potentiates a Crohn's Disease Pathobiont to Fuel Ongoing Inflammation in the Post-Infectious Period. PLoS Pathog (2016) 0.75
Prenatal and perinatal characteristics associated with pediatric-onset inflammatory bowel disease. Dig Dis Sci (2012) 0.75
Making sense of the cause of Crohn's - a new look at an old disease. F1000Res (2016) 0.75
Convergence of External Crohn's Disease Risk Factors on Intestinal Bacteria. Front Immunol (2015) 0.75
Role of Salmonella enterica exposure in Chilean Crohn's disease patients. World J Gastroenterol (2013) 0.75
Infections Requiring Hospitalization as Predictors of Pediatric-Onset Crohn's Disease and Ulcerative Colitis. Gastroenterol Res Pract (2015) 0.75
Profiling of Campylobacter jejuni Proteome in Exponential and Stationary Phase of Growth. Front Microbiol (2017) 0.75
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet (2010) 17.38
Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet (2011) 7.98
Validity of the general practice research database. Pharmacotherapy (2003) 6.78
Narrow-band imaging as an alternative to chromoendoscopy for the detection of dysplasia in long-standing inflammatory bowel disease: a prospective, randomized, crossover study. Gastrointest Endosc (2011) 2.96
Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. J Am Coll Cardiol (2008) 2.82
Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. Am J Gastroenterol (2009) 2.53
Risk of developing tuberculosis under anti-TNF treatment despite latent infection screening. J Crohns Colitis (2012) 2.21
Long-term use of anti-inflammatory drugs and risk of atrial fibrillation. Arch Intern Med (2010) 2.12
Use of acid-suppressing drugs and the risk of bacterial gastroenteritis. Clin Gastroenterol Hepatol (2007) 1.95
Magnetic resonance imaging for evaluation of Crohn's disease: validation of parameters of severity and quantitative index of activity. Inflamm Bowel Dis (2010) 1.91
Life events and inflammatory bowel disease relapse: a prospective study of patients enrolled in remission. Am J Gastroenterol (2006) 1.71
Transcriptional analysis of the intestinal mucosa of patients with ulcerative colitis in remission reveals lasting epithelial cell alterations. Gut (2012) 1.68
Neutrophil infiltration increases matrix metalloproteinase-9 in the ischemic brain after occlusion/reperfusion of the middle cerebral artery in rats. J Cereb Blood Flow Metab (2003) 1.55
[Incidence rate of community acquired pneumonia in a population cohort registered in BIFAP]. Aten Primaria (2010) 1.46
Risk of uncomplicated peptic ulcer among users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs. Am J Epidemiol (2004) 1.42
Incidence and risk factors for atrial fibrillation in patients with newly diagnosed heart failure. J Cardiovasc Med (Hagerstown) (2016) 1.38
Crohn's disease patients carrying Nod2/CARD15 gene variants have an increased and early need for first surgery due to stricturing disease and higher rate of surgical recurrence. Ann Surg (2005) 1.33
Superoxide dismutase ameliorates TNBS-induced colitis by reducing oxidative stress, adhesion molecule expression, and leukocyte recruitment into the inflamed intestine. J Leukoc Biol (2004) 1.28
Morbidity associated with sleep disorders in primary care: a longitudinal cohort study. Prim Care Companion J Clin Psychiatry (2007) 1.23
Prevalence and factors related to hepatitis B and C in inflammatory bowel disease patients in Spain: a nationwide, multicenter study. Am J Gastroenterol (2009) 1.23
Optimising monitoring in the management of Crohn's disease: a physician's perspective. J Crohns Colitis (2013) 1.20
Relative roles of ICAM-1 and VCAM-1 in the pathogenesis of experimental radiation-induced intestinal inflammation. Int J Radiat Oncol Biol Phys (2003) 1.19
Recurrent obstructive apneas trigger early systemic inflammation in a rat model of sleep apnea. Respir Physiol Neurobiol (2006) 1.15
Geriatric drug therapy and healthcare utilization in the United kingdom. Ann Pharmacother (2002) 1.15
Prevalence, incidence, morbidity and treatment patterns in a cohort of patients diagnosed with anxiety in UK primary care. Fam Pract (2009) 1.10
Association between captopril, other antihypertensive drugs and risk of prostate cancer. Prostate (2004) 1.08
Anti-VCAM-1 antibodies did not protect against ischemic damage either in rats or in mice. J Cereb Blood Flow Metab (2006) 1.08
The incidence of bleeding complications associated with warfarin treatment in general practice in the United Kingdom. Br J Gen Pract (2003) 1.08
Direct evidence of leukocyte adhesion in arterioles by angiotensin II. Blood (2004) 1.08
Acid-suppressive drugs and community-acquired pneumonia. Epidemiology (2009) 1.06
Study of a cohort of patients newly diagnosed with depression in general practice: prevalence, incidence, comorbidity, and treatment patterns. Prim Care Companion J Clin Psychiatry (2010) 1.06
Relationship between gastroesophageal reflux disease and COPD in UK primary care. Chest (2008) 1.05
NSAID use selectively increases the risk of non-fatal myocardial infarction: a systematic review of randomised trials and observational studies. PLoS One (2011) 1.04
Nonsteroidal antiinflammatory drugs as a trigger of clinical heart failure. Epidemiology (2003) 1.03
Risk of irritable bowel syndrome after an episode of bacterial gastroenteritis in general practice: influence of comorbidities. Clin Gastroenterol Hepatol (2007) 1.00
The role of P-selectin in experimental colitis as determined by antibody immunoblockade and genetically deficient mice. J Leukoc Biol (2002) 1.00
Results of the 2nd part Scientific Workshop of the ECCO. II: Measures and markers of prediction to achieve, detect, and monitor intestinal healing in inflammatory bowel disease. J Crohns Colitis (2011) 0.99
Defective IL-10 production in severe phenotypes of Crohn's disease. J Leukoc Biol (2009) 0.99
Chronic disease, functional status, and self-ascribed causes of disabilities among noninstitutionalized older people in Spain. J Gerontol A Biol Sci Med Sci (2002) 0.97
Case validation in research using large databases. Br J Gen Pract (2010) 0.94
Health-related quality of life in inflammatory bowel disease patients: the role of psychopathology and personality. Inflamm Bowel Dis (2008) 0.94
Dyspepsia in general practice: incidence, risk factors, comorbidity and mortality. Fam Pract (2007) 0.92
Imaging indexes of activity and severity for Crohn's disease: current status and future trends. Abdom Imaging (2012) 0.92
Effect of cyclosporin A on cell adhesion molecules and leukocyte-endothelial cell interactions in experimental colitis. Inflamm Bowel Dis (2004) 0.91
A genome-wide association study on a southern European population identifies a new Crohn's disease susceptibility locus at RBX1-EP300. Gut (2012) 0.90
Observational study on the efficacy of adalimumab for the treatment of ulcerative colitis and predictors of outcome. J Crohns Colitis (2012) 0.90
Down-regulation of endothelial adhesion molecules and leukocyte adhesion by treatment with superoxide dismutase is beneficial in chronic immune experimental colitis. Inflamm Bowel Dis (2005) 0.89
Role of 3.0-T MR colonography in the evaluation of inflammatory bowel disease. Radiographics (2009) 0.89
Risk factors and characteristics of extent progression in ulcerative colitis. Inflamm Bowel Dis (2009) 0.87
Anti-inflammatory effects of low-dose radiotherapy in an experimental model of systemic inflammation in mice. Int J Radiat Oncol Biol Phys (2006) 0.86
Perception gaps between patients with ulcerative colitis and healthcare professionals: an online survey. BMC Gastroenterol (2012) 0.86
Clinical implications of COX-1 and/or COX-2 inhibition for the distal gastrointestinal tract. Curr Pharm Des (2003) 0.86
Probiotic sonicates selectively induce mucosal immune cells apoptosis through ceramide generation via neutral sphingomyelinase. PLoS One (2011) 0.86
Evaluation of responsive gene expression as a sensitive and specific biomarker in patients with ulcerative colitis. Inflamm Bowel Dis (2013) 0.82
Risk factors for hyperkalaemia in a cohort of patients with newly diagnosed heart failure: a nested case-control study in UK general practice. Eur J Heart Fail (2015) 0.81
Nitric oxide supplementation ameliorates dextran sulfate sodium-induced colitis in mice. Lab Invest (2002) 0.81
Steroid-refractory ulcerative colitis: predictive factors of response to cyclosporine and validation in an independent cohort. Inflamm Bowel Dis (2008) 0.81
Trefoil peptide TFF2 treatment reduces VCAM-1 expression and leukocyte recruitment in experimental intestinal inflammation. J Leukoc Biol (2003) 0.81
Fructose-1,6-biphosphate and nucleoside pool modifications prevent neutrophil accumulation in the reperfused intestine. J Leukoc Biol (2003) 0.81
Protective effect of superoxide dismutase in radiation-induced intestinal inflammation. Int J Radiat Oncol Biol Phys (2005) 0.80
Time course of anti-inflammatory effect of low-dose radiotherapy: correlation with TGF-beta(1) expression. Radiother Oncol (2007) 0.80
Gram-negative enterobacteria induce tolerogenic maturation in dexamethasone conditioned dendritic cells. PLoS One (2012) 0.80
National differences in ulcerative colitis experience and management among patients from five European countries and Canada: an online survey. J Crohns Colitis (2012) 0.80
[Dendritic cells: a new horizon in cell therapy for inflammatory bowel disease?]. Gastroenterol Hepatol (2011) 0.79
Leukocyte recruitment in colon cancer: role of cell adhesion molecules, nitric oxide, and transforming growth factor beta1. Gastroenterology (2002) 0.79
Cell therapies for IBD: what works? Curr Drug Targets (2013) 0.79
Cell therapies for inflammatory bowel diseases. Expert Rev Gastroenterol Hepatol (2009) 0.79
Corrigendum: Characterization of inflammation and fibrosis in Crohn's disease lesions by magnetic resonance imaging. Am J Gastroenterol (2015) 0.78
Lactobacillus casei prevents the upregulation of ICAM-1 expression and leukocyte recruitment in experimental colitis. Am J Physiol Gastrointest Liver Physiol (2006) 0.78
[The Hirsch's h-index: a new tool for measuring scientific production]. Cir Esp (2009) 0.78
[The impact of anxiety and depression on relapse in patients with inflammatory bowel disease]. Med Clin (Barc) (2009) 0.77
Rituximab in active ulcerative colitis. Gastroenterology (2011) 0.77
Are we giving biologics too late? The case for early versus late use. World J Gastroenterol (2008) 0.77
Telomerase mRNA expression and immunohistochemical detection as a biomarker of malignant transformation in patients with inflammatory bowel disease. Gastroenterol Hepatol (2010) 0.77
Study of the association between hip fracture and acid-suppressive drug use in a UK primary care setting. Pharmacotherapy (2014) 0.76
Psychometric properties of the original Inflammatory Bowel Disease Questionnaire, a Spanish version. Gastroenterol Hepatol (2007) 0.76
Idiopathic myelofibrosis associated with ulcerative colitis. Leuk Lymphoma (2002) 0.76
Anti-TNF antibody therapy in Crohn's disease: the risk of a switch. Gut (2011) 0.76
Colonic Crohn's disease: value of magnetic resonance colonography for detection and quantification of disease activity. Abdom Imaging (2009) 0.76
What is Disease Progression in Crohn's Disease and how can it be Measured? J Crohns Colitis (2015) 0.76
Confocal endomicroscopy in celiac disease. Gastroenterology (2011) 0.75
Defects in autophagy induce alterations in the secretory pathway and proinflammatory signaling of paneth cells. Gastroenterology (2009) 0.75
Adalimumab in ulcerative colitis: can pharmacodynamics be improved based on pharmacokinetics? Gastroenterology (2011) 0.75
New imaging standards for evaluation of inflammatory bowel disease? Gastroenterology (2012) 0.75
Toward a safer use of thiopurines in inflammatory bowel disease. Gastroenterology (2010) 0.75
Inflammatory bowel disease (IBD). Preface. Dig Dis (2013) 0.75
Safety and activity of dersalazine sodium in patients with mild-to-moderate active colitis: double-blind randomized proof of concept study. Inflamm Bowel Dis (2014) 0.75
[Rationale for cell therapy in the treatment of inflammatory bowel disease]. Gastroenterol Hepatol (2010) 0.75
Lessons to learn from Crohn's disease clinical trials: implications for ulcerative colitis. Curr Drug Targets (2011) 0.75
MRI of Crohn's disease: from imaging to pathology. Abdom Imaging (2012) 0.75
Cardiovascular disease in immune-mediated inflammatory diseases: A cross-sectional analysis of 6 cohorts. Medicine (Baltimore) (2017) 0.75
Assessment of anti-prothrombin antibodies in thrombosis complicating inflammatory bowel diseases. Int J Colorectal Dis (2013) 0.75
Magnetic resonance enterography in Crohn's disease: optimal use in clinical practice and clinical trials. Scand J Gastroenterol (2015) 0.75
[Scientific publication, bibliometric indicators, and Hirsch's h-index]. Gastroenterol Hepatol (2009) 0.75
[Iron deficiency anemia and use of intravenous iron in digestive disease]. Gastroenterol Hepatol (2010) 0.75
Corrigendum: Diagnostic Performance of the Simple Clinical Colitis Activity Index Self-Administered Online at Home by Patients With Ulcerative Colitis: CRONICA-UC Study. Am J Gastroenterol (2016) 0.75
Treatment patterns among newly diagnosed heart failure patients in general practice. Eur J Clin Pharmacol (2002) 0.75